This suggests that although both CD4+ and CD8+ T cells can mediate CD3 bsAb-mediated tumor cell kill, the dynamics of CD4+ and CD8+ T-cell activation or the distribution of CD4+ and CD8+ T cells may differ between in vitro and in vivo settings. Here, CD8A is linked to neoplasm.